Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda

Laura A. Guay, Philippa Musoke, David L. Hom, Clemensia Nakabiito, Danstan Bagenda, Courtney V. Fletcher, Lawrence H. Marum, Mary Glenn Fowler, Lars G. Falksveden, Britta Wahren, Peter Kataaha, Hans Wigzell, Francis A. Mmiro, J. Brooks Jackson

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the safety, tolerance, pharmacokinetics, and virologic and immunologic changes associated with the use of Ugandan HIV hyperimmune globulin (HIVIGLOB) in HIV infected pregnant Ugandan women and their infants. Design: A prospective, phase I/II, three-arm dose escalation trial of HIVIGLOB. Methods: HIVIGLOB was prepared from discarded HIV infected units of blood collected from the National Blood Bank in Kampala. From June 1996 to April 1997, 31 HIV positive pregnant women were enrolled with HIVIGLOB infusions given at 37 weeks gestation and within 16 h of birth for infants. The first 10 mother-infant pairs were infused at a dose of 50 mg/kg, followed by 11 pairs at 200 mg/kg, and 10 pairs at 400 mg/kg. Study participants were followed for 30 months. Results: Thirty-one women and 29 infants were infused with HIVIGLOB. The infusions were safe and well tolerated by the women and their infants at all doses. There were no significant changes in virologic or immunologic parameters after HIVIGLOB infusion. Pharmacokinetic properties of this product were similar to other immune globulin products with a median half-life of 28 days in women and 30 days in infants. Conclusion: An HIV immune globulin product derived from HIV infected Ugandan donors is safe, well tolerated, and has pharmacokinetic properties consistent with other immunoglobulin products. Data suggest that a 400 mg/kg dose of HIVIGLOB would be the most appropriate dose for a subsequent efficacy trial of HIVIGLOB for the prevention of mother to child HIV transmission.

Original languageEnglish (US)
Pages (from-to)1391-1400
Number of pages10
JournalAIDS
Volume16
Issue number10
DOIs
StatePublished - Jul 5 2002

Keywords

  • Africa
  • HIV hyperimmune globulin
  • HIV vertical transmission
  • Mother to child transmission
  • Uganda

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda'. Together they form a unique fingerprint.

  • Cite this

    Guay, L. A., Musoke, P., Hom, D. L., Nakabiito, C., Bagenda, D., Fletcher, C. V., Marum, L. H., Fowler, M. G., Falksveden, L. G., Wahren, B., Kataaha, P., Wigzell, H., Mmiro, F. A., & Brooks Jackson, J. (2002). Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS, 16(10), 1391-1400. https://doi.org/10.1097/00002030-200207050-00011